Compare Stocks: MRKR, CYPH, RNTX, and PMVP

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CYPH Cypherpunk Technologies	$0.64 -0.6%	$0.68	$0.25 ▼ $3.70	$69.83M	0.09	1.29 million shs	561,961 shs
MRKR Marker Therapeutics	$1.14 +2.7%	$1.32	$0.81 ▼ $2.46	$18.51M	1.5	46,149 shs	45,559 shs
PMVP PMV Pharmaceuticals	$1.26 +3.7%	$1.20	$1.02 ▼ $1.88	$64.80M	1.34	307,718 shs	189,817 shs
RNTX Rein Therapeutics	$0.81 +2.3%	$0.89	$0.69 ▼ $2.18	$67.36M	1.39	424,245 shs	211,019 shs

The Best Nuclear Energy Stocks to Buy

Nuclear energy is entering a new growth cycle as rising power demand, expanding data centers, and renewed policy support bring the sector back into focus. After strong gains in recent years, the most impactful phase of nuclear investment may still be ahead. This report highlights seven nuclear energy stocks positioned across the value chain—combining near-term revenue with long-term upside as next-generation technologies scale. Click the link below to unlock the full list.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CYPH Cypherpunk Technologies	-0.62%	-6.48%	-14.42%	-40.65%	+89.97%
MRKR Marker Therapeutics	+2.70%	+1.79%	-19.15%	-19.72%	-11.63%
PMVP PMV Pharmaceuticals	+3.70%	+5.88%	-10.00%	-2.33%	-17.11%
RNTX Rein Therapeutics	+2.35%	-1.41%	-14.82%	-23.24%	-32.83%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CYPH Cypherpunk Technologies	$0.64 -0.6%	$0.68	$0.25 ▼ $3.70	$69.83M	0.09	1.29 million shs	561,961 shs
MRKR Marker Therapeutics	$1.14 +2.7%	$1.32	$0.81 ▼ $2.46	$18.51M	1.5	46,149 shs	45,559 shs
PMVP PMV Pharmaceuticals	$1.26 +3.7%	$1.20	$1.02 ▼ $1.88	$64.80M	1.34	307,718 shs	189,817 shs
RNTX Rein Therapeutics	$0.81 +2.3%	$0.89	$0.69 ▼ $2.18	$67.36M	1.39	424,245 shs	211,019 shs

The Best Nuclear Energy Stocks to Buy

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CYPH Cypherpunk Technologies	-0.62%	-6.48%	-14.42%	-40.65%	+89.97%
MRKR Marker Therapeutics	+2.70%	+1.79%	-19.15%	-19.72%	-11.63%
PMVP PMV Pharmaceuticals	+3.70%	+5.88%	-10.00%	-2.33%	-17.11%
RNTX Rein Therapeutics	+2.35%	-1.41%	-14.82%	-23.24%	-32.83%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
CYPH Cypherpunk Technologies	2.50	Moderate Buy	$0.90	39.75% Upside
MRKR Marker Therapeutics	2.25	Hold	$10.00	777.19% Upside
PMVP PMV Pharmaceuticals	2.75	Moderate Buy	$4.00	217.46% Upside
RNTX Rein Therapeutics	2.25	Hold	$6.00	644.42% Upside

Current Analyst Ratings Breakdown

Latest MRKR, CYPH, RNTX, and PMVP Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/12/2026	PMVP PMV Pharmaceuticals	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E+) ➝ Sell (D-)
8/6/2026	MRKR Marker Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D-) ➝ Sell (E+)
8/3/2026	RNTX Rein Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E+) ➝ Sell (D-)
7/31/2026	CYPH Cypherpunk Technologies	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D-) ➝ Sell (E+)
7/28/2026	PMVP PMV Pharmaceuticals	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D-) ➝ Sell (E+)
7/20/2026	RNTX Rein Therapeutics	Maxim Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Buy	$4.00
7/17/2026	RNTX Rein Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D-) ➝ Sell (E+)
7/10/2026	CYPH Cypherpunk Technologies	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E+) ➝ Sell (D-)
7/10/2026	PMVP PMV Pharmaceuticals	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E+) ➝ Sell (D-)
7/8/2026	PMVP PMV Pharmaceuticals	LADENBURG THALM/SH SH Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Buy	$3.00
7/3/2026	CYPH Cypherpunk Technologies	Cantor Fitzgerald Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Strong-Buy

(Data available from 8/15/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
CYPH Cypherpunk Technologies	N/A	N/A	N/A	N/A	$1.29 per share	N/A
MRKR Marker Therapeutics	N/A	N/A	N/A	N/A	$1.01 per share	N/A
PMVP PMV Pharmaceuticals	N/A	N/A	N/A	N/A	$1.97 per share	N/A
RNTX Rein Therapeutics	N/A	N/A	$0.06 per share	13.77	($1.07) per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
CYPH Cypherpunk Technologies	$4.82M	$0.56	1.15	N/A	N/A	N/A	-20.76%	-19.48%	N/A
MRKR Marker Therapeutics	-$12.16M	-$0.61	N/A	N/A	N/A	-343.03%	-73.29%	-59.70%	N/A
PMVP PMV Pharmaceuticals	-$77.74M	-$1.49	N/A	N/A	N/A	N/A	-68.98%	-62.70%	N/A
RNTX Rein Therapeutics	-$49.87M	-$1.90	N/A	N/A	N/A	N/A	N/A	-68.14%	N/A

Latest MRKR, CYPH, RNTX, and PMVP Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/14/2026	Q2 2026	MRKR Marker Therapeutics	-$0.25	-$0.09	+$0.16	-$0.09	$0.68 million	N/A
8/14/2026	Q2 2026	RNTX Rein Therapeutics	-$0.27	-$0.10	+$0.17	-$0.10	N/A	N/A
8/13/2026	Q2 2026	PMVP PMV Pharmaceuticals	-$0.3875	-$0.34	+$0.0475	-$0.34	N/A	N/A
8/12/2026	Q2 2026	CYPH Cypherpunk Technologies	N/A	$0.18	N/A	$0.18	N/A	N/A
5/15/2026	Q1 2026	MRKR Marker Therapeutics	-$0.18	-$0.16	+$0.02	-$0.16	$0.78 million	$0.75 million
5/15/2026	Q1 2026	RNTX Rein Therapeutics	-$0.49	-$0.19	+$0.30	-$0.19	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
CYPH Cypherpunk Technologies	N/A	N/A	N/A	N/A	N/A
MRKR Marker Therapeutics	N/A	N/A	N/A	N/A	N/A
PMVP PMV Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
RNTX Rein Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
CYPH Cypherpunk Technologies	N/A	79.19	27.28
MRKR Marker Therapeutics	N/A	4.79	4.79
PMVP PMV Pharmaceuticals	N/A	11.14	11.14
RNTX Rein Therapeutics	N/A	0.40	0.40

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
CYPH Cypherpunk Technologies	30.46%
MRKR Marker Therapeutics	22.39%
PMVP PMV Pharmaceuticals	90.20%
RNTX Rein Therapeutics	90.89%

Insider Ownership

Company	Insider Ownership
CYPH Cypherpunk Technologies	3.50%
MRKR Marker Therapeutics	5.70%
PMVP PMV Pharmaceuticals	10.15%
RNTX Rein Therapeutics	1.50%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
CYPH Cypherpunk Technologies	40	107.76 million	102.74 million	Optionable
MRKR Marker Therapeutics	60	16.67 million	15.72 million	Not Optionable
PMVP PMV Pharmaceuticals	50	53.33 million	47.92 million	Optionable
RNTX Rein Therapeutics	9	85.54 million	84.26 million	N/A

MRKR, CYPH, RNTX, and PMVP Headlines

Recent News About These Companies

Rein Therapeutics (NASDAQ:RNTX) Announces Earnings Results

August 14 at 8:40 PM | marketbeat.com

Rein Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Update

August 14 at 6:44 AM | globenewswire.com

Rein Therapeutics Inc. (NASDAQ:RNTX) Given Consensus Recommendation of "Hold" by Brokerages

August 14 at 6:13 AM | marketbeat.com

Rein Therapeutics (NASDAQ:RNTX) Shares Down 2.9% - Here's Why

August 10, 2026 | marketbeat.com

Rein Therapeutics Announces Publication of Landmark LTI-03 Clinical Data in Nature Communications

August 4, 2026 | finance.yahoo.com

Rein Therapeutics Announces Phase 2 RENEW Trial Now Enrolling Across All Five Countries

July 21, 2026 | globenewswire.com

Rein Therapeutics Inc. (NASDAQ:RNTX) Receives Average Rating of "Hold" from Brokerages

July 20, 2026 | marketbeat.com

Maxim Group Begins Coverage on Rein Therapeutics (NASDAQ:RNTX)

July 20, 2026 | marketbeat.com

Rein Therapeutics (RNTX) Stock Forecast & Price Target

July 17, 2026 | investing.com

Rein Therapeutics, Inc

June 29, 2026 | edition.cnn.com

All You Need to Know About Rein Therapeutics Inc. (RNTX) Rating Upgrade to Buy

June 17, 2026 | zacks.com

Rein Therapeutics Expands Phase 2 RENEW Trial into United Kingdom

June 11, 2026 | globenewswire.com

Rein Therapeutics Inc RNTX

June 7, 2026 | morningstar.comM

Rein Therapeutics (NASDAQ:RNTX) Director Buys $16,747.50 in Stock

May 29, 2026 | insidertrades.com

Rein Therapeutics Announces Closing of $57.5 Million Underwritten Public Offering, Including Full Exercise of Over-Allotment Option

May 18, 2026 | globenewswire.com

Insider Buying: Rein Therapeutics (NASDAQ:RNTX) Insider Purchases 25,000 Shares of Stock

May 14, 2026 | insidertrades.com

Rein Therapeutics Announces Pricing of $50 Million Underwritten Public Offering of Common Stock

April 30, 2026 | globenewswire.com

Rein Therapeutics Provides Clinical Trial Update for Phase 2 RENEW Study of LTI-03 in Idiopathic Pulmonary Fibrosis

April 29, 2026 | globenewswire.com

Rein Therapeutics Stock Short Interest Report | NASDAQ:RNTX | Benzinga

April 14, 2026 | benzinga.com

Rein Therapeutics Doses First Patient in Phase 2 Trial of LTI-03 for Idiopathic Pulmonary Fibrosis

March 3, 2026 | markets.businessinsider.com

Rein Therapeutics (RNTX) price target increased by 25.00% to 10.20

February 4, 2026 | msn.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

MRKR, CYPH, RNTX, and PMVP Company Descriptions

Cypherpunk Technologies NASDAQ:CYPH

$0.64 0.00 (-0.62%)

As of 08/14/2026 04:00 PM Eastern

Leap Therapeutics, Inc., a biopharmaceutical company, acquires and develops antibody therapies for the treatment of cancer. Its lead product candidates include DKN-01, a monoclonal antibody that inhibits Dickkopf-related protein 1, which is in multiple ongoing clinical trials for treating esophagogastric and gynecologic cancers; and FL-301, a monoclonal antibody that targets cells that express Claudin18.2 on their cell surface and is in phase II clinical trial, as well as two preclinical antibody programs, FL-302 and FL-501. Leap Therapeutics, Inc. has an option and license agreement with NovaRock, Adimab, and BeiGene, Ltd. to develop and commercialize DKN-01 in Asia (excluding Japan), Australia, and New Zealand. The company was formerly known as HealthCare Pharmaceuticals, Inc. and changed its name to Leap Therapeutics, Inc. in November 2015. Leap Therapeutics, Inc. was incorporated in 2011 and is based in Cambridge, Massachusetts.

Marker Therapeutics NASDAQ:MRKR

$1.14 +0.03 (+2.70%)

Closing price 08/14/2026 04:00 PM Eastern

Extended Trading

$1.14 0.00 (-0.09%)

As of 08/14/2026 07:56 PM Eastern

Marker Therapeutics, Inc., a clinical-stage immuno-oncology company, engages in the development and commercialization of novel T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications. Its multi tumor associated antigen-specific T cell technology is based on the manufacture of non-engineered tumor-specific T cells that recognize multiple tumor-associated antigens. The company also develops MT-401-OTS for the treatment of acute myeloid leukemia; and MT-601 to treat lymphoma and pancreatic cancer. Marker Therapeutics, Inc. is headquartered in Houston, Texas.

PMV Pharmaceuticals NASDAQ:PMVP

$1.26 +0.05 (+3.70%)

Closing price 08/14/2026 04:00 PM Eastern

Extended Trading

$1.26 0.00 (0.00%)

As of 08/14/2026 04:22 PM Eastern

PMV Pharmaceuticals, Inc., a precision oncology company, engages in the discovery and development of small molecule and tumor-agnostic therapies for p53 mutations in cancer. It's lead product candidate is PC14586, a small molecule that corrects mutant p53 protein containing the Y220C mutation and restores wild-type p53 function. The company was formerly known as PJ Pharmaceuticals, Inc. and changed its name to PMV Pharmaceuticals, Inc. in July 2013. PMV Pharmaceuticals, Inc. was incorporated in 2013 and is based in Princeton, New Jersey.

Rein Therapeutics NASDAQ:RNTX

$0.81 +0.02 (+2.35%)

Closing price 08/14/2026 04:00 PM Eastern

Extended Trading

$0.82 +0.01 (+1.49%)

As of 08/14/2026 07:37 PM Eastern

Rein Therapeutics, Inc. is a clinical stage biopharmaceutical company, which engages in the development and commercialization of a novel class of therapeutics for the treatment of cancer and other diseases. It focuses on its lead product candidate, ALRN-6924, which is a cell-permeating peptide that disrupts the interaction of p53 suppressors MDM2 and MDMX with tumor suppressor p53 to reactivate tumor suppression in non-mutant, or wild-type, p53 cancers. The company was founded by Gregory L. Verdine, Rosana Kapeller, Huw M. Nash, Joseph A. Yanchik III, and Loren David Walensky on August 6, 2001 and is headquartered in Austin, TX.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest MRKR, CYPH, RNTX, and PMVP Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest MRKR, CYPH, RNTX, and PMVP Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

MRKR, CYPH, RNTX, and PMVP Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

MRKR, CYPH, RNTX, and PMVP Company Descriptions

Cypherpunk Technologies NASDAQ:CYPH

Marker Therapeutics NASDAQ:MRKR

PMV Pharmaceuticals NASDAQ:PMVP

Rein Therapeutics NASDAQ:RNTX

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest MRKR, CYPH, RNTX, and PMVP Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest MRKR, CYPH, RNTX, and PMVP Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

MRKR, CYPH, RNTX, and PMVP Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

MRKR, CYPH, RNTX, and PMVP Company Descriptions

Cypherpunk Technologies NASDAQ:CYPH

Marker Therapeutics NASDAQ:MRKR

PMV Pharmaceuticals NASDAQ:PMVP

Rein Therapeutics NASDAQ:RNTX

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools